IIM
ARTV

INTECH Investment Management’s Artiva Biotherapeutics ARTV Stock Holding History

INTECH Investment Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,547
Closed -$34.6K – 2705
2025
Q1 		$34.6K Buy
+11,547
New +$62.3K ﹤0.01% 2468

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

INTECH Investment Management's ARTV Position: Q2 2025 in Review

INTECH Investment Management sold out of Artiva Biotherapeutics (ARTV) in Q2 2025, closing a stake of 11,547 shares — an estimated $34.6K sold.

INTECH Investment Management first reported a position in ARTV in Q1 2025 and held it in 1 quarter. The position peaked at $34.6K in Q1 2025. 48 funds tracked by Wall St. Rank hold ARTV as of Q2 2025.

  • INTECH Investment Management reported no remaining Artiva Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 11,547 Artiva Biotherapeutics shares in Q2 2025, an estimated $34.6K.
  • INTECH Investment Management first reported a position in Artiva Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • INTECH Investment Management's Artiva Biotherapeutics position peaked at $34.6K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.